Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 1/20 | 0.54 |
| ▸ | CDK4 | P11802 | 1/20 | 0.54 |
| ▸ | CDK2 | P24941 | 1/20 | 0.54 |
| ▸ | XDH | P47989 | 1/20 | 0.53 |
| ▸ | PNP | P00491 | 3/20 | 0.48 |
| ▸ | TYMP | P19971 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | MITF | O75030 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | HBB | P68871 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.42 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.41 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.41 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.41 |
| ▸ | QTRT1 | Q9BXR0 | 1/20 | 0.41 |
| ▸ | TYMS | P04818 | 4/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1687020 | 0.79 | XDH (0.49) | CDK1CDK4CDK2XDHPNP | |
| SCHEMBL1271646 | 0.77 | CDK1 (0.56) | CDK1CDK4CDK2PNPMAPT | |
| Hydrochloric Acid SCHEMBL12474436 | 0.75 | CDK1 (0.54) | CDK1CDK4CDK2PNPMAPT | |
| SCHEMBL15971642 | 0.74 | XDH (0.45) | CDK1CDK4CDK2XDHPNP | |
| SCHEMBL17959973 | 0.74 | ALDH1A1 (0.48) | CDK1CDK4CDK2XDHPNP | |
| SCHEMBL3180710 | 0.73 | CDK1 (0.52) | CDK1CDK4CDK2PNPMAPT | |
| SCHEMBL12956972 | 0.73 | CDK1 (0.52) | CDK1CDK4CDK2XDHPNP | |
| SCHEMBL17926747 | 0.72 | XDH (0.42) | CDK1CDK4CDK2XDHPNP | |
| Bropirimine SCHEMBL509127 | 0.71 | XDH (1.00) | XDHMAPTQTRT1 | |
| SCHEMBL29954149 | 0.70 | CDK1 (0.48) | CDK1CDK4CDK2PNPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6562969-B1 | Ricin A-chain is an N-glycosidase that attacks ribosomal RNA at a highly conserved adenine residue. Crystallographic studies show that not only adenine and formycin, but also pterin-based rings can bind in the ricin active site. | RESEARCH DEVELOPMENT FOUNDATION | 2003-05-13 | — | — | US | disclosed |
| US-20020173515-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | VARNEY MICHAEL D (US) | 2002-11-21 | — | — | US | disclosed |
| US-6323210-B2 | TRANSFERASE INHIBITOR | AGOURON PHARMACEUTICALS, INC. | 2001-11-27 | — | — | US | disclosed |
| WO-2001073438-A1 | RICIN INHIBITORS AND METHODS FOR USE THEREOF | RESEARCH DEVELOPMENT FOUNDATION (US) | 2001-10-04 | — | — | WO | disclosed |
| US-20010018443-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | VARNEY MICHAEL D (US) | 2001-08-30 | — | — | US | disclosed |
| EP-0681584-B1 | CONDENSED HETEROCYCLIC GLUTAMIC ACID DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | AGOURON PHARMA (US) | 2001-06-06 | — | — | EP | disclosed |
| EP-1094066-A2 | Condensed heterocyclic glutamic acid derivatives as antiproliferative agents | AGOURON PHARMACEUTICALS, INC. (US) | 2001-04-25 | — | — | EP | disclosed |
| US-6207670-B1 | USE TO INHIBIT GROWTH AND PROLIFERATION OF CELLS OF HIGHER ORGANISMS AND MICROORGANISMS SUCH AS BACTERIA, YEAST AND FUNGI | AGOURON PHARMACEUTICALS, INC. | 2001-03-27 | — | — | US | disclosed |
| EP-0674516-B1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMA (US) | 2000-02-02 | — | — | EP | disclosed |
| US-5945427-A | INHIBIT GROWTH AND PROLIFERATION OF CELLS OF HIGHER ORGANISMS AND MICRORGANISMS SUCH AS FUNGI, BACTERIA AND YEASTS; TREATMENT FOR TUMORS, INFLAMMATION, PSORIASIS; IMMUNOSUPPRESSIVE ACTIVITY | AGOURON PHARMACEUTICALS, INC. (US) | 1999-08-31 | — | — | US | disclosed |
| US-5639749-A | INHIBITORS OF GLYCINAMIDE RIBONUCLEOTIDE FORMYL TRANSFERASE; ANTITUMOR AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1997-06-17 | — | — | US | disclosed |
| US-5625061-A | GRAFT=GLYCINAMIDE RIBONCLEOTIDE FORMYL TRANSFERASE | AGOURON PHARMACEUTICALS, INC. (US) | 1997-04-29 | — | — | US | disclosed |
| US-5610319-A | Compound useful as antiproliferative agents and GARFT inhibitors | AGOURON PHARMACEUTICALS, INC. (US) | 1997-03-11 | — | — | US | disclosed |
| US-5594139-A | FROM 5-HAL-2,6-DIAMINO-3H-4-OXOPYRIMIDINE | AGOURON PHARMACEUTICALS, INC. (US) | 1997-01-14 | — | — | US | disclosed |
| CN-1117295-A | Condensed heterocyclic glutamic acid derivatives as antiproliferative agents | AGOURON PHARMA (US) | 1996-02-21 | — | — | CN | disclosed |
| EP-0681584-A1 | CONDENSED HETEROCYCLIC GLUTAMIC ACID DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-11-15 | — | — | EP | disclosed |
| EP-0674516-A4 | — | — | 1995-10-25 | — | — | EP | disclosed |
| EP-0674516-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1995-10-04 | — | — | EP | disclosed |
| WO-1994017076-A1 | CONDENSED HETEROCYCLIC GLUTAMIC ACID DERIVATIVES AS ANTIPROLIFERATIVE AGENTS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-08-04 | — | — | WO | disclosed |
| WO-1994013295-A1 | ANTIPROLIFERATIVE SUBSTITUTED 5-THIAPYRIMIDINONE AND 5-SELENOPYRIMIDINONE COMPOUNDS | AGOURON PHARMACEUTICALS, INC. (US) | 1994-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010018443-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | GART, GARS1, NUDT1 | CDK1 872/4885CDK4 780/4885CDK2 765/4885 |
| US-20020173515-A1 | Antiproliferative substituted 5-thiapyrimidinone and 5-selenopyrimidinone compounds | GART, GARS1, NUDT1 | CDK1 872/4885CDK4 780/4885CDK2 765/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.